Drug intelligence / Profile preview

OW177

Development stage: Discontinued
Lead developer: Octagon Therapeutics
Modality: Small Molecules

Overview

**OW177** is a small molecule therapeutic developed by Octagon Therapeutics targeting B-cell driven autoimmune diseases, including systemic lupus erythematosus. It aims to restore normal tonic B cell homeostasis by selectively blocking a specific protein-protein interaction critical for aberrant B cell activity. The program represents Octagon's small molecule approach in parallel with their biologic efforts, though development emphasis has shifted toward antibodies.

Beyond the preview

Go deeper on OW177.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OW177.

Explore the full profile